vorinostat has been researched along with Cutaneous T-Cell Lymphoma in 54 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Excerpt | Relevance | Reference |
---|---|---|
"Mogamulizumab significantly prolonged progression-free survival compared with vorinostat, and could provide a new, effective treatment for patients with mycosis fungoides and, importantly, for Sézary syndrome, a subtype that represents a major therapeutic challenge in cutaneous T-cell lymphoma." | 9.27 | Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. ( Bagot, M; Dalle, S; Duvic, M; Dwyer, K; Elmets, C; Eradat, H; Fierro, MT; Fisher, DC; Geskin, LJ; Grebennik, DO; Greer, J; Halwani, A; Horwitz, SM; Hudgens, S; Humphrey, JS; Khot, A; Kim, EJ; Kim, YH; Leoni, M; Moriya, J; Morris, S; Moskowitz, AJ; Musiek, A; Ortiz-Romero, PL; Pinter-Brown, L; Poligone, B; Porcu, P; Pro, B; Rook, AH; Scarisbrick, J; Shustov, A; Sokol, L; Tobinai, K; Tokura, Y; Tsianakas, A; Vermeer, M; Whittaker, S; Zinzani, PL, 2018) |
"The retinoid X receptor (RXR)-agonist bexarotene and the histone deacetylase inhibitor (HDACI) vorinostat are each established monotherapies for cutaneous T-cell lymphomas (CTCLs)." | 9.16 | Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition. ( Ahern, JD; Assaf, C; Baumann, K; Bernards, R; Beyer, M; Dummer, R; Epping, MT; Frankel, SR; Garcia-Vargas, J; Hardwick, JS; Heath, K; Hymes, K; Kerl, H; Rizvi, S; Steinhoff, M; Sterry, W; Whittaker, SJ, 2012) |
"A phase I study was conducted to evaluate the safety, tolerability, pharmacokinetics (PK) and efficacy of the oral histone deacetylase (HDAC) inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL)." | 9.16 | Phase I and pharmacokinetic study of the oral histone deacetylase inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T-cell lymphoma. ( Hamada, T; Iwatsuki, K; Kato, Y; Noguchi, K; Shimamoto, T; Sugaya, M; Tobinai, K; Tsuboi, R; Wada, H, 2012) |
"Vorinostat, an orally active histone deacetylase inhibitor, was approved in October 2006 by the US Food and Drug Administration for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL) in patients with progressive, persistent, or recurrent disease during or after treatment with 2 systemic therapies." | 9.14 | Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma. ( Abuav, R; Boileau, K; Breneman, D; Chen, C; Duvic, M; Geskin, LJ; Gunchenko, A; Olsen, EA; Pacheco, TR; Parker, S; Ricker, JL; Rizvi, S; Sanz-Rodriguez, C; Vonderheid, EC, 2009) |
"The activity and safety of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid, SAHA) were evaluated in patients with refractory cutaneous T-cell lymphoma (CTCL)." | 9.12 | Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). ( Chiao, JH; Duvic, M; Frankel, SR; Hazarika, P; Kelly, C; Ni, X; Reilly, JF; Richon, VM; Ricker, JL; Talpur, R; Zhang, C, 2007) |
"To evaluate the activity and safety of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in persistent, progressive, or recurrent mycosis fungoides or Sézary syndrome (MF/SS) cutaneous t-cell lymphoma (CTCL) subtypes." | 9.12 | Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. ( Arduino, JM; Chen, C; Duvic, M; Foss, FM; Frankel, SR; Kim, YH; Kuzel, TM; Olsen, EA; Pacheco, TR; Parker, S; Ricker, JL, 2007) |
" The Food and Drug Administration has approved two HDAC inhibitors, vorinostat (2006) and romidepsin (2009), for the treatment of cutaneous T-cell lymphoma." | 8.93 | The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies. ( Dimopoulos, M; Duvic, M, 2016) |
"The pharmacology, pharmacokinetics, clinical efficacy, safety, adverse effects, dosage and administration, and role in therapy of vorinostat in the treatment of cutaneous T-cell lymphoma (CTCL) are reviewed." | 8.86 | Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma. ( Kavanaugh, SA; Kavanaugh, SM; Kolesar, JM; White, LA, 2010) |
" Vorinostat (suberoylanilide hydroxamic acid) is the first FDA-approved HDAC inhibitor for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL)." | 8.84 | Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. ( Duvic, M; Vu, J, 2007) |
"Vorinostat and romidepsin are histone deacetylase inhibitors (HDI), approved for the treatment of cutaneous T-cell lymphoma (CTCL)." | 7.77 | The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells. ( Adams, J; Ganesan, A; Hodges, E; Packham, G; Tiffon, C; Townsend, P; van der Fits, L; Vermeer, M; Wen, S, 2011) |
"Vorinostat (suberoylanilide hydroxamic acid, SAHA), an inhibitor of class I and II histone deacetylases, has been approved for the treatment of cutaneous T-cell lymphoma." | 7.76 | Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma. ( Aparicio, CB; Bischoff, JR; de La Cueva, P; Herrera, M; Herreros, B; Longo, MI; Martin-Perez, D; Martínez Leal, JF; Ortiz-Romero, PL; Piris, MA; Rodriguez, ME; Villuendas, R; Wozniak, MB, 2010) |
"To discuss vorinostat approval for treatment of cutaneous manifestations of advanced cutaneous T-cell lymphoma (CTCL)." | 7.74 | Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. ( Abraham, S; Booth, BP; Dagher, R; Farrell, A; Harapanhalli, RS; He, K; Jee, JM; Johnson, JR; Justice, R; Mann, BS; Morse, DE; Pazdur, R; Pope, S; Sridhara, R; Verbois, L, 2007) |
"Vorinostat was active against solid tumors and hematologic malignancies as intravenous and oral preparations in phase I development." | 6.44 | Vorinostat in cutaneous T-cell lymphoma. ( Duvic, M; Vu, J, 2007) |
"Mogamulizumab significantly prolonged progression-free survival compared with vorinostat, and could provide a new, effective treatment for patients with mycosis fungoides and, importantly, for Sézary syndrome, a subtype that represents a major therapeutic challenge in cutaneous T-cell lymphoma." | 5.27 | Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. ( Bagot, M; Dalle, S; Duvic, M; Dwyer, K; Elmets, C; Eradat, H; Fierro, MT; Fisher, DC; Geskin, LJ; Grebennik, DO; Greer, J; Halwani, A; Horwitz, SM; Hudgens, S; Humphrey, JS; Khot, A; Kim, EJ; Kim, YH; Leoni, M; Moriya, J; Morris, S; Moskowitz, AJ; Musiek, A; Ortiz-Romero, PL; Pinter-Brown, L; Poligone, B; Porcu, P; Pro, B; Rook, AH; Scarisbrick, J; Shustov, A; Sokol, L; Tobinai, K; Tokura, Y; Tsianakas, A; Vermeer, M; Whittaker, S; Zinzani, PL, 2018) |
"The retinoid X receptor (RXR)-agonist bexarotene and the histone deacetylase inhibitor (HDACI) vorinostat are each established monotherapies for cutaneous T-cell lymphomas (CTCLs)." | 5.16 | Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition. ( Ahern, JD; Assaf, C; Baumann, K; Bernards, R; Beyer, M; Dummer, R; Epping, MT; Frankel, SR; Garcia-Vargas, J; Hardwick, JS; Heath, K; Hymes, K; Kerl, H; Rizvi, S; Steinhoff, M; Sterry, W; Whittaker, SJ, 2012) |
"A phase I study was conducted to evaluate the safety, tolerability, pharmacokinetics (PK) and efficacy of the oral histone deacetylase (HDAC) inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL)." | 5.16 | Phase I and pharmacokinetic study of the oral histone deacetylase inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T-cell lymphoma. ( Hamada, T; Iwatsuki, K; Kato, Y; Noguchi, K; Shimamoto, T; Sugaya, M; Tobinai, K; Tsuboi, R; Wada, H, 2012) |
"Vorinostat, an orally active histone deacetylase inhibitor, was approved in October 2006 by the US Food and Drug Administration for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL) in patients with progressive, persistent, or recurrent disease during or after treatment with 2 systemic therapies." | 5.14 | Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma. ( Abuav, R; Boileau, K; Breneman, D; Chen, C; Duvic, M; Geskin, LJ; Gunchenko, A; Olsen, EA; Pacheco, TR; Parker, S; Ricker, JL; Rizvi, S; Sanz-Rodriguez, C; Vonderheid, EC, 2009) |
"The activity and safety of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid, SAHA) were evaluated in patients with refractory cutaneous T-cell lymphoma (CTCL)." | 5.12 | Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). ( Chiao, JH; Duvic, M; Frankel, SR; Hazarika, P; Kelly, C; Ni, X; Reilly, JF; Richon, VM; Ricker, JL; Talpur, R; Zhang, C, 2007) |
"To evaluate the activity and safety of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in persistent, progressive, or recurrent mycosis fungoides or Sézary syndrome (MF/SS) cutaneous t-cell lymphoma (CTCL) subtypes." | 5.12 | Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. ( Arduino, JM; Chen, C; Duvic, M; Foss, FM; Frankel, SR; Kim, YH; Kuzel, TM; Olsen, EA; Pacheco, TR; Parker, S; Ricker, JL, 2007) |
" The Food and Drug Administration has approved two HDAC inhibitors, vorinostat (2006) and romidepsin (2009), for the treatment of cutaneous T-cell lymphoma." | 4.93 | The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies. ( Dimopoulos, M; Duvic, M, 2016) |
" Food and Drug Administration, vorinostat and romidepsin, both with indications for cutaneous T-cell lymphoma." | 4.89 | Histone deacetylase inhibitors: novel agents in cancer treatment. ( Glass, E; Viale, PH, 2013) |
" The hydroxamic acid derivative SAHA (also known as vorinostat or Zolinza®) and the cyclic depsipeptide FK228 (romidepsin or Istodax®) have gained approval from the US FDA for the treatment of cutaneous T-cell lymphoma." | 4.88 | Current trends in the development of histone deacetylase inhibitors: a review of recent patent applications. ( Thaler, F, 2012) |
"Vorinostat is a histone deacetylase inhibitor used in the treatment of recurrent or persistent cases of cutaneous T-cell lymphoma (CTCL)." | 4.88 | QT interval prolongation and torsades de pointes in a patient undergoing treatment with vorinostat: a case report and review of the literature. ( Lynch, DR; Newby, LK; Washam, JB, 2012) |
"The pharmacology, pharmacokinetics, clinical efficacy, safety, adverse effects, dosage and administration, and role in therapy of vorinostat in the treatment of cutaneous T-cell lymphoma (CTCL) are reviewed." | 4.86 | Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma. ( Kavanaugh, SA; Kavanaugh, SM; Kolesar, JM; White, LA, 2010) |
" Hematological malignancies seem to be particularly sensitive, and vorinostat (also called suberoylanilide hydroxamic acid) has recently been approved for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients with progressive, persistent or recurrent disease." | 4.84 | Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas. ( Khan, O; La Thangue, NB, 2008) |
" Vorinostat (suberoylanilide hydroxamic acid) is the first FDA-approved HDAC inhibitor for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL)." | 4.84 | Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. ( Duvic, M; Vu, J, 2007) |
"Vorinostat and romidepsin are histone deacetylase inhibitors (HDI), approved for the treatment of cutaneous T-cell lymphoma (CTCL)." | 3.77 | The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells. ( Adams, J; Ganesan, A; Hodges, E; Packham, G; Tiffon, C; Townsend, P; van der Fits, L; Vermeer, M; Wen, S, 2011) |
"Vorinostat (suberoylanilide hydroxamic acid, SAHA), an inhibitor of class I and II histone deacetylases, has been approved for the treatment of cutaneous T-cell lymphoma." | 3.76 | Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma. ( Aparicio, CB; Bischoff, JR; de La Cueva, P; Herrera, M; Herreros, B; Longo, MI; Martin-Perez, D; Martínez Leal, JF; Ortiz-Romero, PL; Piris, MA; Rodriguez, ME; Villuendas, R; Wozniak, MB, 2010) |
"To discuss vorinostat approval for treatment of cutaneous manifestations of advanced cutaneous T-cell lymphoma (CTCL)." | 3.74 | Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. ( Abraham, S; Booth, BP; Dagher, R; Farrell, A; Harapanhalli, RS; He, K; Jee, JM; Johnson, JR; Justice, R; Mann, BS; Morse, DE; Pazdur, R; Pope, S; Sridhara, R; Verbois, L, 2007) |
"Vorinostat is a histone deacetylase inhibitor that has demonstrated preclinical activity in numerous cancer models." | 2.49 | Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor. ( Agrawal, NG; Friedman, EJ; Iwamoto, M; Rubin, EH; Sandhu, P; Wagner, JA, 2013) |
"Vorinostat was approved in the United States in 2006 for the treatment of cutaneous manifestations of T-cell lymphoma in patients with progressive, persistent, or recurrent disease on or following 2 systemic therapies." | 2.46 | The role of histone deacetylase inhibitors in the treatment of patients with cutaneous T-cell lymphoma. ( Hymes, KB, 2010) |
"Vorinostat was active against solid tumors and hematologic malignancies as intravenous and oral preparations in phase I development." | 2.44 | Vorinostat in cutaneous T-cell lymphoma. ( Duvic, M; Vu, J, 2007) |
"This study was conducted to identify novel therapeutic targets that can be combined with HDACis for treating CTCL." | 1.62 | Kinome profiling analysis identified Src pathway as a novel therapeutic target in combination with histone deacetylase inhibitors for cutaneous T-cell lymphoma. ( Fujii, K; Jimura, N; Kanekura, T; Kondo, T; Qiao, Z; Tsuchiya, R; Yoshimatsu, Y, 2021) |
"Pruritus is one of the cardinal symptoms found in patients with leukemic cutaneous T cell lymphoma (CTCL)." | 1.42 | Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities. ( Benoit, BM; Cedeno-Laurent, F; Kim, EJ; Rook, AH; Singer, EM; Vittorio, CC; Wysocka, M; Yosipovitch, G, 2015) |
" The extreme photopotency of UVASens allows the use of lower radiation doses minimising the carcinogenic risks associated with the long-term use of phototherapy." | 1.40 | Histone deacetylase inhibitors potentiate photochemotherapy in cutaneous T-cell lymphoma MyLa cells. ( Karagiannis, TC; Sung, JJ; Ververis, K, 2014) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 17 (31.48) | 29.6817 |
2010's | 31 (57.41) | 24.3611 |
2020's | 6 (11.11) | 2.80 |
Authors | Studies |
---|---|
Fournier, JF | 1 |
Bhurruth-Alcor, Y | 1 |
Musicki, B | 1 |
Aubert, J | 1 |
Aurelly, M | 1 |
Bouix-Peter, C | 1 |
Bouquet, K | 1 |
Chantalat, L | 1 |
Delorme, M | 1 |
Drean, B | 1 |
Duvert, G | 1 |
Fleury-Bregeot, N | 1 |
Gauthier, B | 1 |
Grisendi, K | 1 |
Harris, CS | 1 |
Hennequin, LF | 1 |
Isabet, T | 1 |
Joly, F | 1 |
Lafitte, G | 1 |
Millois, C | 1 |
Morgentin, R | 1 |
Pascau, J | 1 |
Piwnica, D | 1 |
Rival, Y | 1 |
Soulet, C | 1 |
Thoreau, É | 1 |
Tomas, L | 1 |
Fujii, K | 2 |
Idogawa, M | 1 |
Suzuki, N | 1 |
Iwatsuki, K | 2 |
Kanekura, T | 2 |
Beylot-Barry, M | 1 |
Booken, N | 1 |
Weishaupt, C | 1 |
Scarisbrick, J | 3 |
Wu, W | 1 |
Rosen, JP | 1 |
Medley, MC | 1 |
Papadopoulou, V | 1 |
Degrauwe, N | 1 |
Decosterd, LA | 1 |
Buclin, T | 1 |
Cairoli, A | 1 |
Bordeaux, ZA | 1 |
Reddy, SV | 1 |
Lee, K | 1 |
Lu, W | 1 |
Choi, J | 1 |
Miller, M | 1 |
Roberts, C | 1 |
Pollizzi, A | 1 |
Kwatra, SG | 1 |
Kwatra, MM | 1 |
Ikumi, N | 1 |
Fujita, H | 1 |
Terui, T | 1 |
Takahashi, H | 1 |
Miura, K | 1 |
Hatta, Y | 1 |
Takei, M | 1 |
Jimura, N | 1 |
Qiao, Z | 1 |
Tsuchiya, R | 1 |
Yoshimatsu, Y | 1 |
Kondo, T | 1 |
Horwitz, S | 1 |
Zinzani, PL | 2 |
Bagot, M | 2 |
Kim, YH | 3 |
Moskowitz, AJ | 2 |
Porcu, P | 2 |
Dwyer, K | 2 |
Sun, W | 1 |
Herr, FM | 1 |
Kießling, MK | 1 |
Nicolay, JP | 1 |
Schlör, T | 1 |
Klemke, CD | 1 |
Süss, D | 1 |
Krammer, PH | 1 |
Gülow, K | 1 |
Cyrenne, BM | 1 |
Lewis, JM | 1 |
Weed, JG | 1 |
Carlson, KR | 1 |
Mirza, FN | 1 |
Foss, FM | 2 |
Girardi, M | 1 |
Geskin, L | 1 |
Malone, DC | 1 |
Gniadecki, R | 1 |
Pinter-Brown, L | 1 |
Rook, AH | 3 |
Horwitz, SM | 1 |
Whittaker, S | 1 |
Tokura, Y | 1 |
Vermeer, M | 2 |
Sokol, L | 1 |
Morris, S | 1 |
Kim, EJ | 3 |
Ortiz-Romero, PL | 2 |
Eradat, H | 1 |
Tsianakas, A | 1 |
Elmets, C | 1 |
Dalle, S | 1 |
Fisher, DC | 1 |
Halwani, A | 1 |
Poligone, B | 1 |
Greer, J | 1 |
Fierro, MT | 1 |
Khot, A | 1 |
Musiek, A | 1 |
Shustov, A | 1 |
Pro, B | 1 |
Geskin, LJ | 2 |
Moriya, J | 1 |
Leoni, M | 1 |
Humphrey, JS | 1 |
Hudgens, S | 1 |
Grebennik, DO | 1 |
Tobinai, K | 2 |
Duvic, M | 10 |
Iwamoto, M | 1 |
Friedman, EJ | 1 |
Sandhu, P | 1 |
Agrawal, NG | 1 |
Rubin, EH | 1 |
Wagner, JA | 1 |
Thaler, F | 1 |
Nihal, M | 1 |
Ahmad, N | 1 |
Wood, GS | 1 |
Sung, JJ | 1 |
Ververis, K | 1 |
Karagiannis, TC | 1 |
Litvinov, IV | 1 |
Cordeiro, B | 1 |
Fredholm, S | 1 |
Ødum, N | 1 |
Zargham, H | 1 |
Huang, Y | 1 |
Zhou, Y | 1 |
Pehr, K | 1 |
Kupper, TS | 1 |
Woetmann, A | 2 |
Sasseville, D | 1 |
Cedeno-Laurent, F | 1 |
Singer, EM | 1 |
Wysocka, M | 1 |
Benoit, BM | 1 |
Vittorio, CC | 2 |
Yosipovitch, G | 1 |
Kitadate, A | 2 |
Ikeda, S | 2 |
Teshima, K | 2 |
Ito, M | 1 |
Toyota, I | 1 |
Hasunuma, N | 1 |
Takahashi, N | 2 |
Miyagaki, T | 2 |
Sugaya, M | 3 |
Tagawa, H | 2 |
Dimopoulos, M | 1 |
Abe, F | 1 |
Yamashita, J | 1 |
Nakanishi, H | 1 |
Asaka, C | 1 |
Heymann, WR | 1 |
Khan, O | 1 |
La Thangue, NB | 1 |
Heider, U | 1 |
Rademacher, J | 1 |
Lamottke, B | 1 |
Mieth, M | 1 |
Moebs, M | 1 |
von Metzler, I | 1 |
Assaf, C | 2 |
Sezer, O | 1 |
Gardner, JM | 1 |
Evans, KG | 1 |
Goldstein, S | 1 |
Olsen, EA | 2 |
Breneman, D | 1 |
Pacheco, TR | 2 |
Parker, S | 2 |
Vonderheid, EC | 1 |
Abuav, R | 1 |
Ricker, JL | 3 |
Rizvi, S | 2 |
Chen, C | 2 |
Boileau, K | 1 |
Gunchenko, A | 1 |
Sanz-Rodriguez, C | 1 |
Wozniak, MB | 1 |
Villuendas, R | 1 |
Bischoff, JR | 1 |
Aparicio, CB | 1 |
Martínez Leal, JF | 1 |
de La Cueva, P | 1 |
Rodriguez, ME | 1 |
Herreros, B | 1 |
Martin-Perez, D | 1 |
Longo, MI | 1 |
Herrera, M | 1 |
Piris, MA | 1 |
Hymes, KB | 1 |
Zirlik, K | 1 |
Nashan, D | 1 |
Veelken, H | 1 |
Kavanaugh, SM | 1 |
Kavanaugh, SA | 1 |
White, LA | 1 |
Kolesar, JM | 1 |
Krejsgaard, T | 1 |
Kopp, K | 1 |
Ralfkiaer, E | 1 |
Willumsgaard, AE | 1 |
Eriksen, KW | 1 |
Labuda, T | 1 |
Rasmussen, S | 1 |
Mathiesen, AM | 1 |
Geisler, C | 1 |
Lauenborg, B | 1 |
Becker, JC | 1 |
Zhang, Q | 1 |
Wasik, MA | 1 |
Odum, N | 1 |
Zain, J | 1 |
Kaminetzky, D | 1 |
O'Connor, OA | 1 |
Tiffon, C | 1 |
Adams, J | 1 |
van der Fits, L | 1 |
Wen, S | 1 |
Townsend, P | 1 |
Ganesan, A | 1 |
Hodges, E | 1 |
Packham, G | 1 |
Dummer, R | 1 |
Beyer, M | 1 |
Hymes, K | 1 |
Epping, MT | 1 |
Bernards, R | 1 |
Steinhoff, M | 1 |
Sterry, W | 2 |
Kerl, H | 1 |
Heath, K | 1 |
Ahern, JD | 1 |
Hardwick, JS | 1 |
Garcia-Vargas, J | 1 |
Baumann, K | 1 |
Frankel, SR | 3 |
Whittaker, SJ | 1 |
Wada, H | 1 |
Tsuboi, R | 1 |
Kato, Y | 1 |
Hamada, T | 1 |
Shimamoto, T | 1 |
Noguchi, K | 1 |
Al-Yacoub, N | 1 |
Fecker, LF | 1 |
Möbs, M | 1 |
Plötz, M | 1 |
Braun, FK | 1 |
Eberle, J | 1 |
Lynch, DR | 1 |
Washam, JB | 1 |
Newby, LK | 1 |
Giannini, G | 1 |
Cabri, W | 1 |
Fattorusso, C | 1 |
Rodriquez, M | 1 |
Marks, P | 1 |
Glass, E | 1 |
Viale, PH | 1 |
Zhang, C | 2 |
Richon, V | 1 |
Ni, X | 2 |
Talpur, R | 2 |
Hazarika, P | 1 |
Kelly, C | 1 |
Chiao, JH | 1 |
Reilly, JF | 1 |
Richon, VM | 1 |
Thompson, CA | 1 |
Grant, S | 1 |
Easley, C | 1 |
Kirkpatrick, P | 1 |
Mann, BS | 2 |
Johnson, JR | 2 |
He, K | 1 |
Sridhara, R | 1 |
Abraham, S | 1 |
Booth, BP | 1 |
Verbois, L | 1 |
Morse, DE | 1 |
Jee, JM | 1 |
Pope, S | 1 |
Harapanhalli, RS | 1 |
Dagher, R | 1 |
Farrell, A | 1 |
Justice, R | 2 |
Pazdur, R | 2 |
Kuzel, TM | 1 |
Arduino, JM | 1 |
Vu, J | 2 |
Scheinfeld, N | 1 |
Cohen, MH | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 (Mogamulizumab) Versus Vorinostat in Subjects With Previously Treated Cutaneous T-Cell Lymphoma[NCT01728805] | Phase 3 | 372 participants (Actual) | Interventional | 2012-11-30 | Completed | ||
Phase II Study of Mogamulizumab With DA-EPOCH in Patients With Aggressive T Cell Lymphoma[NCT05996185] | Phase 2 | 36 participants (Anticipated) | Interventional | 2024-01-31 | Not yet recruiting | ||
A Continuation Clinical Trial of Oral Vorinostat (MK-0683) in Advanced Cancers[NCT00907738] | Phase 2 | 27 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
A Phase I Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (Vorinostat; Zolinza) in Combination With Bexarotene in Patients With Advanced Cutaneous T-Cell Lymphoma[NCT00127101] | Phase 1 | 23 participants (Actual) | Interventional | 2005-09-30 | Terminated (stopped due to The study was stopped due to low enrollment.) | ||
Phase I Clinical Study of MK-0683 in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL)[NCT00771472] | Phase 1 | 10 participants (Actual) | Interventional | 2008-08-31 | Completed | ||
Phase IIb Multicenter Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Advanced Cutaneous T-cell Lymphoma[NCT00091559] | Phase 2 | 74 participants (Actual) | Interventional | 2005-02-03 | Completed | ||
A Phase I/II Study of Vorinostat (Zolinza®) in Combination With Capecitabine (X) and Cisplatin (P) for 1st Line Treatment of Metastatic or Recurrent Gastric Cancer[NCT01045538] | Phase 1/Phase 2 | 45 participants (Actual) | Interventional | 2010-02-28 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
"The Itchy QoL is a validated pruritus specific quality of life instrument. It includes 22 pruritus-specific questions covering three major domains: symptoms, functioning, and emotions. The scale ranges from Never (1) to All The Time (5). The subscale scores consist of the average of the responses to the items in a given subscale. The overall score is the average of the responses to all items. Higher Itchy QoL scores indicate worse quality of life.~LS mean (and 95% CI) of the overall change from baseline across time points through 6-month assessment (including End of Cycles 1, 3, and 5 time points only) are calculated from MMRM with treatment, disease type, disease stage, and region as fixed effects and baseline score as a covariate." (NCT01728805)
Timeframe: Cycle 1, 3, and 5
Intervention | score on a scale (Least Squares Mean) |
---|---|
KW-0761 | -0.5 |
Vorinostat | -0.4 |
The ORR was defined as the count of subjects who had a confirmed CR or PR, defined as documented CR or PR per Global Composite Response Score that was confirmed by a subsequent observation at least 4 weeks later. Overall Response Rate was determined based on the response in all compartments (lymph nodes, skin, peripheral blood, and viscera), referencing Olsen, 2011 as follows: Complete Response (CR) = complete disappearance of all clinical evidence of disease; Partial Response (PR) = regression of measurable disease; Stable Disease (SD) = failure to attain CR, PR, or PD; Progressive Disease (PD) = PD in any compartment; Relapse = recurrence of disease in prior CR in any compartment. (NCT01728805)
Timeframe: at the end of cycle 1 (26-28 days), and then every other cycle in Year 1 (cycle 3, 5, 7, 9, 11, 13), and every 16 weeks (cycle 17, 21, etc.) in Year 2 and beyond until progression up to 36 months
Intervention | Participants (Count of Participants) | ||
---|---|---|---|
All Subjects ORR (confirmed CR + PR) | Disease Type = MF ORR (confirmed CR + PR) | Disease Type = SS ORR (confirmed CR + PR) | |
KW-0761 | 52 | 22 | 30 |
Vorinostat | 9 | 7 | 2 |
"Progression was defined as follows, based on Olsen (2011):~Lymph nodes: ≥ 50% increase in SPD from baseline of lymph nodes, any new node > 1.5 cm in the long axis or > 1 cm in the short axis if 1-1.5 cm in the long axis that is proven to be N3 histologically, or > 50% increase from nadir in SPD of lymph nodes in those with PR~Skin: ≥ 25% increase in skin disease from baseline, new tumors (T3) in patients with T1, T2 or T4 only skin disease, or in those with CR or PR, increase of skin score of greater than the sum of nadir plus 50% baseline score~Blood: B0 to B2, > 50% increase from baseline and at least 5,000 neoplastic cells/μL36, or > 50% increase from nadir and at least 5,000 neoplastic cells/μL~Viscera: > 50% increase in size (SPD) of any organs involved at baseline, new organ involvement, or > 50% increase from nadir in the size (SPD) of any previous organ involvement in those with PR" (NCT01728805)
Timeframe: From date of randomization at every visit until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months
Intervention | percentage of subjects (Number) | ||||
---|---|---|---|---|---|
Rate (%) of Being Alive w/o Progression at 6 mos. | Rate (%) of Being Alive w/o Progression at 12 mos. | Rate (%) of Being Alive w/o Progression at 18 mos. | Rate (%) of Being Alive w/o Progression at 24 mos. | Rate (%) of Being Alive w/o Progression at 30 mos. | |
KW-0761 | 55.3 | 38.3 | 28.0 | 14.1 | 4.7 |
Vorinostat | 28.8 | 15.3 | 7.2 | 7.2 | 7.2 |
"Skindex-29 rates 29 items assessing 3 domains (emotions, symptoms, & functioning) on a linear scale from 0 (never) to all the time (100). Higher scores = higher impact of skin disease.~FACT-G rates 27 items in 4 domains (physical well-being, social/family well-being, emotional well-being, functional well-being) on a 5-point scale from 0 (not at all) to 4 (very much). Higher scores = better QoL.~EuroQoL lvl 3 (Eq-5D-3L) rates mobility, self-care, usual activities, pain/discomfort and anxiety/depression on 3 levels - no problems, some problems, extreme problems. Score is calculated using a set of item weights to derive a single score ranging from -0.109 to 1, with 1 representing full health.~LS mean (and 95% CI) of the overall change from baseline across time points through 6-month assessment (including End of Cycles 1, 3, and 5 time points only) are calculated from MMRM with treatment, disease type, disease stage, and region as fixed effects and baseline score as a covariate." (NCT01728805)
Timeframe: Cycle 1, 3, and 5
Intervention | score on a scale (Least Squares Mean) | ||
---|---|---|---|
Skindex-29 Across 6-month Assessment | FACT-G Across 6-month Assessment | EQ-5D-3L Across 6-month Assessment | |
KW-0761 | -12.6 | 4.6 | 0.06 |
Vorinostat | -6.0 | -2.3 | 0.02 |
"A serious adverse event (SAE) was any AE occurring at any dose that resulted in death, was life-threatening, resulted in a persistent or significant disability/incapacity, resulted in or prolonged an existing inpatient hospitalization, was a congenital anomaly/birth defect, was a cancer, or was an overdose.~A drug-related SAE was one that was thought to be possibly, probably, or definitely related to the study drug." (NCT00907738)
Timeframe: From the first dose of study drug until the patient experiences disease progression, withdraws consent, or develops unacceptable toxicity (from Day 1 up to 4 years and 9 months)
Intervention | percent of participants (Number) |
---|---|
Base Protocol 001 | 7.7 |
Base Protocol 006 | 0 |
Base Protocol 008 | 0 |
Base Protocol 012 | 0 |
Base Protocol 013 | 0 |
Number of patients with Dose Limiting Toxicities (DLT). A DLT is an adverse event that determined the treatment dose level was not tolerable for that patient in Cycle 1. (NCT00127101)
Timeframe: Day 1 to day 28
Intervention | Participants (Number) | |
---|---|---|
DLT | No DLT | |
Cohort 1 | 0 | 3 |
Cohort 2 | 2 | 3 |
Cohort 2a | 0 | 3 |
Cohort 2b | 0 | 3 |
Cohort 6 | 0 | 5 |
Cohort 7 | 1 | 2 |
"Disease burden as assessed by the pre-specified Severity Weighted Assessment Tool (SWAT) measurement. A Response is defined as equal to or greater than 50% improvement in SWAT score.~SWAT Score is determined by the Lesions classified as patch, plaque, or tumor. The sum of percent of total body surface area (%TBSA) by lesion type is derived and multiplied by a factor of 1 (for patch), 2 (for plaque), or 4 (for tumor). The skin score total is derived by summing the skin score subtotals for patches, plaques and tumors. The skin score total is dimensionless and can range from 0 to 400" (NCT00127101)
Timeframe: Every 28 days for up to 6 Months of Treatment
Intervention | Participants (Number) | |
---|---|---|
Response | No Response | |
Cohort 1 | 0 | 3 |
Cohort 2 | 0 | 5 |
Cohort 2a | 0 | 3 |
Cohort 2b | 1 | 2 |
Cohort 6 | 2 | 3 |
Cohort 7 | 1 | 2 |
"A DLT was defined as any of the following (per Common Terminology Criteria for Adverse Events [CTCAE] version 3.0):~Grade 3 (severe)-4 (life-threatening) neutropenia with fever ≥ 38.5ºC~Grade 3-4 neutropenia with an infection requiring antibiotic or antifungal treatment~Grade 4 neutropenia lasting at least 5 days~Grade 4 thrombocytopenia~Other Grade 4 hematologic toxicity, including a decrease in hemoglobin, only at the discretion of the principal investigator~Grade 3 or 4 non-hematologic event, except which are manageable by supportive care or non-prohibited therapies" (NCT00771472)
Timeframe: Day 1 to Day 28
Intervention | participants (Number) |
---|---|
Vorinostat | 1 |
"Blood samples taken as follows:~Day 1 & Day 28 of Cycle 1: pre dose, and 0.25, 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 10, 12 and 24 hours after dosing of vorinostat." (NCT00771472)
Timeframe: Days 1 & 28 of Cycle 1
Intervention | µM (Geometric Mean) | |
---|---|---|
Day 1 (n=6) | Day 28 (n=5) | |
Vorinostat | 0.83 | 1.17 |
"Blood samples taken as follows:~Day 1 & Day 28 of Cycle 1: pre dose, and 0.25, 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 10, 12 and 24 hours after dosing of vorinostat." (NCT00771472)
Timeframe: Days 1 & 28 of Cycle 1
Intervention | hours (Geometric Mean) | |
---|---|---|
Day 1 (n=5) | Day 28 (n=4) | |
Vorinostat | 1.94 | 2.30 |
"Blood samples taken as follows:~Day 1 & Day 28 of Cycle 1: pre dose, and 0.25, 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 10, 12 and 24 hours after dosing of vorinostat." (NCT00771472)
Timeframe: Days 1 & 28 of Cycle 1
Intervention | hours (Median) | |
---|---|---|
Day 1 (n=6) | Day 28 (n=5) | |
Vorinostat | 2.91 | 3.73 |
"Blood samples taken as follows:~Day 1 & Day 28 of Cycle 1: pre dose, and 0.25, 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 10, 12 and 24 hours after dosing of vorinostat." (NCT00771472)
Timeframe: Days 1 & 28 of Cycle 1
Intervention | µM*hr (Geometric Mean) | |
---|---|---|
Day 1 (n=6) | Day 28 (n=5) | |
Vorinostat | 4.59 | 5.59 |
A laboratory AE is defined as any unfavorable & unintended change in the chemistry of the body temporally associated with the use of study product, whether or not considered related to the use of the product. A clinical AE is defined similarly but also includes changes in structure or function of the body. (NCT00771472)
Timeframe: Day 1 up until 30 days post study completion or early termination (up to approximately 506 days)
Intervention | participants (Number) | |
---|---|---|
Clinical AEs | Laboratory AEs | |
Vorinostat | 10 | 6 |
17 reviews available for vorinostat and Cutaneous T-Cell Lymphoma
Article | Year |
---|---|
Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor.
Topics: Dose-Response Relationship, Drug; Drug Interactions; Histone Deacetylase Inhibitors; Humans; Hydroxa | 2013 |
Current trends in the development of histone deacetylase inhibitors: a review of recent patent applications.
Topics: Animals; Antineoplastic Agents; Depsipeptides; Drug Approval; Histone Deacetylase Inhibitors; Histon | 2012 |
Histone Deacetylase Inhibitors for Cutaneous T-Cell Lymphoma.
Topics: Depsipeptides; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Lymphoma, T-Cell, | 2015 |
The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Depsipeptides; Disease Management; Hematologic Neoplas | 2016 |
Treatment of cutaneous T-cell lymphoma: focus on vorinostat.
Topics: Antineoplastic Agents; Fatigue; Gastrointestinal Diseases; Histone Deacetylase Inhibitors; Humans; H | 2008 |
Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas.
Topics: Antineoplastic Agents; Histone Deacetylases; Humans; Hydroxamic Acids; Lymphoma, T-Cell, Cutaneous; | 2008 |
The role of histone deacetylase inhibitors in the treatment of patients with cutaneous T-cell lymphoma.
Topics: Antineoplastic Agents; Depsipeptides; Hematologic Neoplasms; Histone Deacetylase Inhibitors; Humans; | 2010 |
[Vorinostat in the treatment of cutaneous T-cell lymphomas. Treatment with histone deacetylases inhibitors].
Topics: Antineoplastic Agents; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lymphoma, T-Cell, C | 2010 |
Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Histone Deacetylase Inhibitors; Humans; Hydroxamic | 2010 |
Emerging role of epigenetic therapies in cutaneous T-cell lymphomas.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Depsipeptides; Epigenesis, Genetic; Histone Deacety | 2010 |
QT interval prolongation and torsades de pointes in a patient undergoing treatment with vorinostat: a case report and review of the literature.
Topics: Antineoplastic Agents; Doxepin; Electrocardiography; Histone Deacetylase Inhibitors; Humans; Hydroxa | 2012 |
Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives.
Topics: Antineoplastic Agents; Apoptosis; Depsipeptides; Drug Design; Drug Therapy, Combination; Histone Dea | 2012 |
Histone deacetylase inhibitors: novel agents in cancer treatment.
Topics: Antineoplastic Agents; Depsipeptides; Education, Nursing, Continuing; Histone Deacetylase Inhibitors | 2013 |
Systemic monotherapy vs combination therapy for CTCL: rationale and future strategies.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antine | 2007 |
Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma.
Topics: Administration, Oral; Animals; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic | 2007 |
A brief primer on treatments of cutaneous T cell lymphoma, newly approved or late in development.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bexarotene; Diphtheria Toxin; Drug Approv | 2007 |
Vorinostat in cutaneous T-cell lymphoma.
Topics: Animals; Antineoplastic Agents; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lymphoma, | 2007 |
9 trials available for vorinostat and Cutaneous T-Cell Lymphoma
Article | Year |
---|---|
Impact of blood involvement on efficacy and time to response with mogamulizumab in mycosis fungoides and Sézary syndrome.
Topics: Humans; Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides; Sezary Syndrome; Skin Neoplasms; Vorinostat | 2023 |
Lack of impact of type and extent of prior therapy on outcomes of mogamulizumab therapy in patients with cutaneous T cell lymphoma in the MAVORIC trial.
Topics: Antibodies, Monoclonal, Humanized; Humans; Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides; Sezary Sy | 2021 |
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Australia; Drug Admin | 2018 |
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Australia; Drug Admin | 2018 |
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Australia; Drug Admin | 2018 |
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Australia; Drug Admin | 2018 |
Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma.
Topics: Aged; Antineoplastic Agents; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lymph | 2009 |
Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Cell Line, Tumor; Cell Surv | 2012 |
Phase I and pharmacokinetic study of the oral histone deacetylase inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T-cell lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Histone Deacetylase Inhibitors; Humans; Hydroxamic | 2012 |
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dehydration; Disease Progression; Disease-Fre | 2007 |
Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Confidence Intervals; Dose-Response Relationsh | 2007 |
FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dose-Response Relations | 2007 |
28 other studies available for vorinostat and Cutaneous T-Cell Lymphoma
Article | Year |
---|---|
Squaramides as novel class I and IIB histone deacetylase inhibitors for topical treatment of cutaneous t-cell lymphoma.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Dose | 2018 |
Functional Depletion of HSP72 by siRNA and Quercetin Enhances Vorinostat-Induced Apoptosis in an HSP72-Overexpressing Cutaneous T-Cell Lymphoma Cell Line, Hut78.
Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Gene | 2021 |
Simultaneous kinetics of oral vorinostat in plasma and cerebrospinal fluid in a patient with cutaneous T-cell lymphoma with CNS involvement.
Topics: Antineoplastic Agents; Humans; Kinetics; Lymphoma, T-Cell, Cutaneous; Skin Neoplasms; Vorinostat | 2023 |
Differential Response of Mycosis Fungoides Cells to Vorinostat.
Topics: Humans; Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides; Proteomics; Skin Neoplasms; Vorinostat | 2023 |
Aggressive CD4-CD8-CD45RA+CCR10- Primary Cutaneous Peripheral T-cell Lymphoma, Not Otherwise Specified: A Case Report.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; CD4 Antigens; CD8 Antigens; Disease Progression; Fat | 2019 |
Kinome profiling analysis identified Src pathway as a novel therapeutic target in combination with histone deacetylase inhibitors for cutaneous T-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Depsipeptides; Drug Scr | 2021 |
NRAS mutations in cutaneous T cell lymphoma (CTCL) sensitize tumors towards treatment with the multikinase inhibitor Sorafenib.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; | 2017 |
Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients.
Topics: Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Depsipeptides; Drug Screening Assays, Ant | 2017 |
An exploratory cost-effectiveness analysis of systemic treatments for cutaneous T-cell lymphoma.
Topics: Antineoplastic Agents; Bexarotene; Cost-Benefit Analysis; Diphtheria Toxin; Humans; Hydroxamic Acids | 2018 |
CCR4-targeted therapy in cutaneous T-cell lymphoma.
Topics: Antibodies, Monoclonal, Humanized; Humans; Lymphoma, T-Cell, Cutaneous; Receptors, CCR4; Vorinostat | 2018 |
SIRT1 is upregulated in cutaneous T-cell lymphoma, and its inhibition induces growth arrest and apoptosis.
Topics: Acetanilides; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; | 2014 |
Histone deacetylase inhibitors potentiate photochemotherapy in cutaneous T-cell lymphoma MyLa cells.
Topics: Benzamides; Cell Death; Cell Survival; DNA Damage; DNA Repair; Histone Deacetylase Inhibitors; Human | 2014 |
Analysis of STAT4 expression in cutaneous T-cell lymphoma (CTCL) patients and patient-derived cell lines.
Topics: Cell Line, Tumor; Depsipeptides; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; | 2014 |
Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities.
Topics: Adult; Aged; Aged, 80 and over; Depsipeptides; Dexamethasone; Female; Histone Deacetylase Inhibitors | 2015 |
MicroRNA-16 mediates the regulation of a senescence-apoptosis switch in cutaneous T-cell and other non-Hodgkin lymphomas.
Topics: Animals; Apoptosis; Blotting, Western; Cell Line, Tumor; Cellular Senescence; Cyclin-Dependent Kinas | 2016 |
Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Female; Gene Expression Regulation, | 2017 |
Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, D | 2009 |
Vorinostat for the treatment of bullous pemphigoid in the setting of advanced, refractory cutaneous T-cell lymphoma.
Topics: Antibodies, Anti-Idiotypic; Antineoplastic Agents; Diagnosis, Differential; Dose-Response Relationsh | 2009 |
Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Cell Proliferat | 2010 |
A novel xenograft model of cutaneous T-cell lymphoma.
Topics: Animals; Antigens, CD; Cell Line, Tumor; Cell Proliferation; Cell Transplantation; Disease Models, A | 2010 |
The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells.
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Depsipeptides; Down-Regulation; Histone Deacetylase Inhibit | 2011 |
Apoptosis induction by SAHA in cutaneous T-cell lymphoma cells is related to downregulation of c-FLIP and enhanced TRAIL signaling.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; CASP8 and FADD-Like Apoptosis Regulating Protein; Do | 2012 |
A conversation with Paul Marks. Interview by Ushma S. Neill.
Topics: Antineoplastic Agents; Cancer Care Facilities; Glucosephosphate Dehydrogenase Deficiency; Hematology | 2012 |
Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action.
Topics: Acetylation; Antineoplastic Agents; Apoptosis; Caspase 3; Caspases; Cell Line, Tumor; Cyclin-Depende | 2005 |
Vorinostat approved for rare lymphoma.
Topics: Antineoplastic Agents; Drug Approval; Drug Labeling; Enzyme Inhibitors; Histone Deacetylase Inhibito | 2006 |
Vorinostat.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Drug Approval; D | 2007 |
Vorinostat (Zolinza) for cutaneous T-Cell lymphoma.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Histone Deacetylase Inhibitors; Humans; Hydroxamic | 2007 |
Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma.
Topics: Animals; Anticarcinogenic Agents; Cats; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II | 2007 |